Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil
Rev. Soc. Bras. Med. Trop
;
52: e20180272, 2019. tab, graf
Article
in English
| LILACS
| ID: biblio-1041550
ABSTRACT
Abstract INTRODUCTION:
Visceral leishmaniasis (VL) is fatal if not diagnosed and treated. This study aimed to estimate the cost-effectiveness of diagnostic-therapeutic alternatives for VL in Brazil.METHODS:
A decision model estimated the life expectancy and costs of six diagnostic-therapeutic strategies.RESULTS:
IT LEISH + liposomal amphotericin B emerged the best option, presenting lower costs and higher effectiveness. DAT-LPC + liposomal amphotericin B showed an incremental cost-effectiveness ratio of US$ 326.31 per life year.CONCLUSIONS:
These findings indicate the feasibility of incorporating DAT and designating liposomal amphotericin B as the first-line drug for VL in Brazil.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Amphotericin B
/
Cost-Benefit Analysis
/
Leishmaniasis, Visceral
/
Meglumine
/
Antiprotozoal Agents
Type of study:
Diagnostic study
/
Health economic evaluation
/
Prognostic study
Limits:
Humans
Country/Region as subject:
South America
/
Brazil
Language:
English
Journal:
Rev. Soc. Bras. Med. Trop
Journal subject:
Tropical Medicine
Year:
2019
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Centro Federal de Educação Tecnológica de Minas Gerais/BR
/
Instituto de Avaliação de Tecnologia em Saúde/BR
/
Pesquisa Clínica e Políticas Públicas em Doenças Infecciosas e Parasitárias/BR
/
Universidade do Estado do Rio de Janeiro/BR
Similar
MEDLINE
...
LILACS
LIS